Promising results for new tuberculosis therapy

Bagchi, Sanjit
January 2008
CMAJ: Canadian Medical Association Journal;1/1/2008, Vol. 178 Issue 1, p19
Academic Journal
The article talks about the possibility of having a shorter duration treatment for tuberculosis as shown in preliminary findings from a clinical trial. The findings show that new combination therapy which includes Moxifloxacin, an antibiotic, has the capability to cut the needed time to sure drug-susceptible tuberculosis to period of four to six months. The mentioned drug is presently in its advanced stage of clinical trials and may possible be on the market by the year 2012 to help nations like India which struggles due to high incidence of tuberculosis.


Related Articles

  • Once-weekly treatment as effective as daily treatment in TB continuation phase.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p19 

    The article discusses the RIFAQUIN study conducted by Dr. Amina Jindani and colleagues which found that once-weekly administration of rifapentine and moxifloxacin for tuberculosis treatment is effective as the standard daily treatment.

  • Antibiotic-resistant Ocular Surface Flora After IVT Injection.  // Review of Ophthalmology;Jul2013, Vol. 20 Issue 7, p71 

    The article offers information on the side-effect of routine use of topical moxifloxacin after intravitreal injection that can lead to an increased antibiotic resistance in ocular surface flora.

  • Moxifloxacin-based regimens for tuberculosis.  // Africa Health;Nov2014, Vol. 37 Issue 1, p51 

    The article discusses the study which aims to determine if the replacement of isoniazid or ethambutol with moxifloxacin is effective in improving rates of adherence and adverse effects on tuberculosis.

  • Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. Dookie, Navisha; Sturm, A. Willem; Moodley, Prashini // Infection & Drug Resistance;2014, Vol. 7, p223 

    Objectives: Moxifloxacin (MXF) has been advocated for the treatment of extensively drugresistant (XDR) tuberculosis despite resistance to older-generation fluoroquinolones. We investigated the relationship between the minimum inhibitory concentration (MIC) of MXF and mutations in the gyrA and...

  • Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). Chuchalin, Alexander; Zakharova, Maryna; Dokic, Dejan; Tokić, Mahir; Marschall, Hans-Peter; Petri, Thomas // BMC Pulmonary Medicine;2013, Vol. 13 Issue 1, p1 

    Background: Acute exacerbations of chronic bronchitis (AECB), including chronic obstructive pulmonary disease (AECOPD), represent a substantial patient burden. Few data exist on outpatient antibiotic management for AECB/ AECOPD in Eastern/South Eastern Europe, in particular on the use of...

  • Moxifloxacin.  // Reactions Weekly;2/27/2010, Issue 1290, p34 

    The article describes the case of five patients who acquired uveitis-like syndrome while undergoing treatment with oral moxifloxacin.

  • Effect of Empirical Treatment With Moxifloxacin and Menopenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis A Randomized Trial. Brunkhorst, Frank M.; Oppert, Michael; Marx, Gernot; Bloos, Frank; Ludewig, Katrin; Putensen, Christian; Nierhaus, Axel; Jaschinski, Ulrich; Meier-Hellmann, Andreas; Weyland, Andreas; Gründling, Matthias; Moerer, Onnen; Riessen, Reimer; Seibel, Armin; Ragaller, Maximilian; Büchler, Markus W.; John, Stefan; Bach, Friedhelm; Spies, Claudia; Reill, Lorenz // JAMA: Journal of the American Medical Association;6/13/2012, Vol. 307 Issue 22, p2390 

    The article presents information on antimicrobial therapy which has lead to the increase in mortality and morbidity in neutropenic fever effected patients with severe sepsis. A comparative study is conducted to understand the effect of meropenem and moxifloxacin and the meropenem when used alone...

  • US government HIV/AIDS clinical trial sites to accelerate completion of phase III TB drug trial.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p673 

    The article reports on the collaboration between TB Alliance and the National Institute of Allergy and Infectious Diseases' (NIAID) AIDS Clinical Trial Group (ACTG), to conduct a Phase III clinical trial for faster-acting tuberculosis (TB) treatments. It mentions that both organizations aim to...

  • Efficacy and Tolerability of Moxifloxacin in 2338 Patients with Acute Exacerbation of Chronic Bronchitis. Barth, J.; Landen, H. // Clinical Drug Investigation;2003, Vol. 23 Issue 1, p1 

    Objective: A post-marketing surveillance (PMS) study was conducted to evaluate the efficacy and tolerability of moxifloxacin 400mg once daily in patients with acute exacerbation of chronic bronchitis (AECB) treated by pulmonologists and pulmonary specialists in community-based practice settings....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics